Conestoga Capital Advisors LLC raised its stake in shares of Azenta, Inc. (NASDAQ:AZTA – Free Report) by 0.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,918,366 shares of the company’s stock after purchasing an additional 2,810 shares during the period. Conestoga Capital Advisors LLC owned 4.19% of Azenta worth $59,047,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd acquired a new position in Azenta during the first quarter worth approximately $505,000. Exchange Traded Concepts LLC increased its position in Azenta by 44.2% during the second quarter. Exchange Traded Concepts LLC now owns 417,597 shares of the company’s stock worth $12,854,000 after purchasing an additional 128,084 shares during the last quarter. Kera Capital Partners Inc. acquired a new position in Azenta during the second quarter worth approximately $321,000. Caxton Associates LLP acquired a new stake in shares of Azenta in the first quarter worth $1,347,000. Finally, Principal Financial Group Inc. increased its position in shares of Azenta by 2.4% in the first quarter. Principal Financial Group Inc. now owns 226,491 shares of the company’s stock worth $7,846,000 after acquiring an additional 5,408 shares in the last quarter. Institutional investors and hedge funds own 99.08% of the company’s stock.
Azenta Price Performance
NASDAQ AZTA opened at $30.97 on Monday. Azenta, Inc. has a 12 month low of $23.91 and a 12 month high of $55.63. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -12.80 and a beta of 1.62. The company’s fifty day moving average price is $30.39 and its two-hundred day moving average price is $29.61.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on the stock. Stephens assumed coverage on shares of Azenta in a research report on Tuesday, July 22nd. They issued an “equal weight” rating and a $35.00 price objective for the company. Raymond James Financial raised shares of Azenta from a “market perform” rating to an “outperform” rating and set a $35.00 price objective for the company in a research report on Wednesday, August 6th. Evercore ISI set a $33.00 price objective on shares of Azenta and gave the stock an “in-line” rating in a research report on Tuesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Azenta in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $35.75.
Get Our Latest Analysis on Azenta
Azenta Profile
Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
Recommended Stories
- Five stocks we like better than Azenta
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall?
- What is the Nikkei 225 index?
- Snap-on Incorporated: Snap It Up Quick, New Highs Will Come Soon
- How to Plot Fibonacci Price Inflection Levels
- As Global Renewables Surpass Coal, This ETF Offers Smart Exposure
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.